Literature DB >> 21545762

A solute gradient in the tear meniscus. II. Implications for lid margin disease, including meibomian gland dysfunction.

Anthony J Bron1, Norihiko Yokoi, Eamonn A Gaffney, John M Tiffany.   

Abstract

We have hypothesized previously that evaporation from the tears generates a solute gradient across the tear meniscus, which delivers hyperosmolar stress to the mucocutaneous junction (MCJ) of the lid margin. This is proposed as the basis for Marx's line, a line of staining with topically applied dyes that lies directly behind the MCJ. In this article, we consider the implications of this hypothesis for progressive damage to the lid margin as an age-related phenomenon, its amplification in dry eye states, and its possible role in the etiology of meibomian gland dysfunction (MGD). It is suggested that a hyperosmolar or related stimulus, acting behind the MCJ over a lifetime, promotes the anterior migration of the MCJ, which is a feature of the aging lid margin. This mechanism would be amplified in dry eye states, not only by reason of increased tear molarity at the meniscus apex but also by raising the concentration of inflammatory peptides at this site. This could explain the increased width and irregularity of Marx's line in dry eye. While the presence of stem cells at the lid margin may equip this region to respond to such stress, their depletion could be the basis of irreversible lid margin damage. It is further proposed, given the proximity of the MCJ to the meibomian gland orifices, that the solute gradient mechanism could play a role in the initiation of MGD by delivering hyperosmolar and inflammatory stresses to the terminal ducts and orifices of the glands. By the same token, the presence of a zone of increased epithelial permeability in this region may provide a back door route for the delivery of drugs in the treatment of MGD.

Entities:  

Mesh:

Year:  2011        PMID: 21545762     DOI: 10.1016/s1542-0124(11)70015-5

Source DB:  PubMed          Journal:  Ocul Surf        ISSN: 1542-0124            Impact factor:   5.033


  7 in total

Review 1.  Meibocyte differentiation and renewal: Insights into novel mechanisms of meibomian gland dysfunction (MGD).

Authors:  Ho Sik Hwang; Geraint J Parfitt; Donald J Brown; James V Jester
Journal:  Exp Eye Res       Date:  2017-02-17       Impact factor: 3.467

Review 2.  TFOS DEWS II Tear Film Report.

Authors:  Mark D P Willcox; Pablo Argüeso; Georgi A Georgiev; Juha M Holopainen; Gordon W Laurie; Tom J Millar; Eric B Papas; Jannick P Rolland; Tannin A Schmidt; Ulrike Stahl; Tatiana Suarez; Lakshman N Subbaraman; Omür Ö Uçakhan; Lyndon Jones
Journal:  Ocul Surf       Date:  2017-07-20       Impact factor: 5.033

3.  Tear Volume-based Diagnostic Classification for Tear Dysfunction.

Authors:  Stephen C Pflugfelder; Koray Gumus; Jason Feuerman; Anastasia Alex
Journal:  Int Ophthalmol Clin       Date:  2017

4.  Correlation Analysis of Ocular Symptoms and Signs in Patients with Dry Eye.

Authors:  Hang Song; Mingzhou Zhang; Xiaodan Hu; Kaixiu Li; Xiaodan Jiang; Yan Liu; Huibin Lv; Xuemin Li
Journal:  J Ophthalmol       Date:  2017-02-20       Impact factor: 1.909

5.  Assessment of meibomian glands using a custom-made meibographer in dry eye patients in Ghana.

Authors:  Eugene Appenteng Osae; Reynolds Kwame Ablorddepey; Jens Horstmann; David Ben Kumah; Philipp Steven
Journal:  BMC Ophthalmol       Date:  2018-08-16       Impact factor: 2.209

6.  Intense Pulsed Light Therapy with Optimal Pulse Technology as an Adjunct Therapy for Moderate to Severe Blepharitis-Associated Keratoconjunctivitis.

Authors:  Fang Ruan; Yunxiao Zang; Ruti Sella; Hongshuang Lu; Shang Li; Ke Yang; Tao Jin; Natalie A Afshari; Zhiqiang Pan; Ying Jie
Journal:  J Ophthalmol       Date:  2019-09-16       Impact factor: 1.909

7.  Relation Between Dietary Essential Fatty Acid Intake and Dry Eye Disease and Meibomian Gland Dysfunction in Postmenopausal Women.

Authors:  Jillian F Ziemanski; Lynn R Wolters; Lisa Jones-Jordan; Jason J Nichols; Kelly K Nichols
Journal:  Am J Ophthalmol       Date:  2018-01-11       Impact factor: 5.258

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.